All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Orion Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19

Lead Product(s): OB-002

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OB-002

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: National Research Council Industrial Research Assistance Program

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding July 30, 2020

Details:

Funding from the National Research Council Industrial Research Assistance Program will support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS).